171 related articles for article (PubMed ID: 25142896)
1. Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging.
Kawaguchi T; Ogawa Y; Tominaga T
BMC Res Notes; 2014 Aug; 7():555. PubMed ID: 25142896
[TBL] [Abstract][Full Text] [Related]
2. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
[TBL] [Abstract][Full Text] [Related]
3. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
Hong JW; Lee MK; Kim SH; Lee EJ
Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
[TBL] [Abstract][Full Text] [Related]
4. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
Kim SI; Yoon JH; Park DC; Yang SH; Kim YI
Int J Med Sci; 2023; 20(4):463-467. PubMed ID: 37057215
[No Abstract] [Full Text] [Related]
5. [Misleading diagnosis of hyperprolactinemia in women].
Paepegaey AC; Veron L; Wimmer MC; Christin-Maitre S
Gynecol Obstet Fertil; 2016 Mar; 44(3):181-6. PubMed ID: 26966035
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.
Cho A; Vila G; Marik W; Klotz S; Wolfsberger S; Micko A
Front Endocrinol (Lausanne); 2022; 13():901385. PubMed ID: 36147567
[TBL] [Abstract][Full Text] [Related]
7. Masked hyperprolactinemia: tumor-derived factors inhibiting prolactin secretion caused by pituitary-stalk damage.
Kinoshita Y; Hama S; Tominaga A; Arita K; Sugiyama K; Sakoguchi T; Usui S; Kurisu K
J Clin Neurosci; 2011 Dec; 18(12):1651-5. PubMed ID: 22015098
[TBL] [Abstract][Full Text] [Related]
8. [Hyperprolactinemia in patients with non-functioning adenoma: analysis of 85 patients treated by transsphenoidal operation].
Saitoh Y; Mori S; Arita N; Hayakawa T; Mogami H; Oku Y; Onishi T; Uozumi T
No Shinkei Geka; 1987 Nov; 15(11):1175-9. PubMed ID: 3437926
[TBL] [Abstract][Full Text] [Related]
9. Serum Prolactin Level to Tumor Size Ratio as a Potential Parameter for Preoperative Differentiation of Prolactinomas from Hyperprolactinemia-Causing Non-functional Pituitary Adenomas.
Kim JH; Hur KY; Hong SD; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
World Neurosurg; 2022 Mar; 159():e488-e496. PubMed ID: 34958988
[TBL] [Abstract][Full Text] [Related]
10. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of extensive spherical amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation.
Levine SN; Ishaq S; Nanda A; Wilson JD; Gonzalez-Toledo E
Ann Diagn Pathol; 2013 Aug; 17(4):361-6. PubMed ID: 23602507
[TBL] [Abstract][Full Text] [Related]
12. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
13. The hook effect in prolactin immunoassays.
Al Sifri SN; Raef H
Saudi Med J; 2004 May; 25(5):656-9. PubMed ID: 15138537
[TBL] [Abstract][Full Text] [Related]
14. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
15. A single- center experience of prolactin-producing pituitary adenomas without hyperprolactinemia: Its incidence and clinical management.
Ogawa Y; Tominaga T
Clin Neurol Neurosurg; 2020 Nov; 198():106123. PubMed ID: 32818756
[TBL] [Abstract][Full Text] [Related]
16. True hyperprolactinemia in men without visible pituitary adenoma.
Shimon I; Rudman Y; Manisterski Y; Gorshtein A; Masri H; Duskin-Bitan H
Endocrine; 2021 Jun; 72(3):809-813. PubMed ID: 33566310
[TBL] [Abstract][Full Text] [Related]
17. Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression.
Zaidi HA; Cote DJ; Castlen JP; Burke WT; Liu YH; Smith TR; Laws ER
World Neurosurg; 2017 Jan; 97():2-7. PubMed ID: 27671881
[TBL] [Abstract][Full Text] [Related]
18. Pituitary adenomas associated with hyperprolactinemia: a clinical and immunohistochemical study of 97 patients operated on transsphenoidally.
Randall RV; Scheithauer BW; Laws ER; Abbound CF; Ebersold MJ; Kao PC
Mayo Clin Proc; 1985 Nov; 60(11):753-62. PubMed ID: 3932786
[TBL] [Abstract][Full Text] [Related]
19. [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
Harms E; Siggelkow H; Buchfelder M; Saeger W; Hüfner M
Dtsch Med Wochenschr; 2003 Mar; 128(13):667-70. PubMed ID: 12660899
[TBL] [Abstract][Full Text] [Related]
20. Hyperprolactinemia: a 12-year retrospective study at gynecologic endocrinology unit, Siriraj Hospital.
Saejong R; Dangrat C; Techatrisak K; Angsuwatthana S; Rattanachaiyanont M; Tanmahasamut P
J Med Assoc Thai; 2013 Oct; 96(10):1247-56. PubMed ID: 24350404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
